Trial failures of Novartis, Novo Nordisk heart drugs puzzle experts

· Health · Switzerland · Denmark

Novartis and co-developer Ionis Pharmaceuticals announced that their drug failed to meet the main goal of a trial, leaving experts guessing about the failures of heart drugs from both Novartis and Novo Nordisk. The setbacks raise questions about the development path for cardiovascular treatments. Novartis is a Swiss pharmaceutical giant, while Denmark's Novo Nordisk has built a large franchise in metabolic and cardiovascular disease. The failures could affect investor expectations for the companies' pipelines.

Why it matters：Setbacks in cardiovascular drug trials matter for the pipelines of two major pharma companies and for patients awaiting new heart treatments.

Key points

  • Novartis and Ionis said their drug missed the trial's main goal.
  • The failure follows setbacks for a Novo Nordisk heart drug.
  • Both companies have large cardiovascular and metabolic franchises.

Sources (original reporting)

More stories from this day